These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19012633)

  • 1. Acute suicidality after commencing atomoxetine.
    Paxton GA; Cranswick NE
    J Paediatr Child Health; 2008 Oct; 44(10):596-8. PubMed ID: 19012633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine use during a period of FDA actions.
    Du DT; Zhou EH; Goldsmith J; Nardinelli C; Hammad TA
    Med Care; 2012 Nov; 50(11):987-92. PubMed ID: 23047788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, dose-titration tolerability study of atomoxetine hydrochloride in Japanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M; Takita Y; Goto T; Ichikawa H; Saito K; Matsumoto H; Tanaka Y
    Psychiatry Clin Neurosci; 2011 Feb; 65(1):55-63. PubMed ID: 21265936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does atomoxetine increase the risk of aggression and hostility in children with attention deficit hyperactivity disorder?
    Banerjee S; Ayyash HF
    Arch Dis Child Educ Pract Ed; 2008 Aug; 93(4):131-2. PubMed ID: 18644903
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased blood pressure and atomoxetine.
    Dworkin N
    J Am Acad Child Adolesc Psychiatry; 2005 Jun; 44(6):510. PubMed ID: 15908831
    [No Abstract]   [Full Text] [Related]  

  • 7. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.
    Saylor K; Williams DW; Schuh KJ; Wietecha L; Greenbaum M
    Curr Med Res Opin; 2010 Sep; 26(9):2087-95. PubMed ID: 20642391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 10. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atomoxetine--Strattera. Oral preparation].
    Duh PD; Macken E
    J Pharm Belg; 2006; 61(4):117-20. PubMed ID: 17263193
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.
    Gökçen C; Kutuk MO; Coşkun Ş
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):428-30. PubMed ID: 23952193
    [No Abstract]   [Full Text] [Related]  

  • 13. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine-induced hyponatremia.
    Singh T
    Aust N Z J Psychiatry; 2007 May; 41(5):458. PubMed ID: 17464740
    [No Abstract]   [Full Text] [Related]  

  • 16. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine-induced mania with auditory hallucination in an 8-year-old boy with attention-deficit/hyperactivity disorder and tic disorder.
    Liu CC; Lan CC; Chen YS
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):466-7. PubMed ID: 25020072
    [No Abstract]   [Full Text] [Related]  

  • 18. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs.
    Bond GR; Garro AC; Gilbert DL
    Clin Toxicol (Phila); 2007; 45(2):182-5. PubMed ID: 17364639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warning on Strattera for attention-deficit hyperactivity disorder.
    FDA Consum; 2005; 39(6):4. PubMed ID: 16671156
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
    Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
    Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.